openPR Logo
Press release

Non-Hodgkin Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma, Eli Lilly

07-29-2025 02:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Non-Hodgkin Lymphoma Pipeline 2025: FDA Updates, Therapy

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes 180+ key companies continuously working towards developing 200 + Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Non-Hodgkin Lymphoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.

The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.

*
Non-Hodgkin Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment

*
Emerging Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.

*
In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced the launch of waveLINE-010, a pivotal Phase 3 clinical trial. This study is evaluating the efficacy of zilovertamab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus the standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The global recruitment for the waveLINE-010 trial is underway, and patient enrollment has begun.

*
In January 2025, The initial patient with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) has received a dose of SynKIR-310 in the Phase 1 CELESTIAL-301 trial (NCT06544265). This early-stage, multicenter study is designed to assess the safety, tolerability, and preliminary effectiveness of SynKIR-310 in individuals with R/R B-NHL, including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.

*
In October 2024, ImmunityBio, Inc. (NASDAQ: IBRX), a pioneer in immunotherapy, has announced the initiation of patient dosing in its early-stage clinical trial evaluating the company's CAR-NK cell therapy targeting CD19 for the treatment of non-Hodgkin's lymphoma (NHL). The Phase 1 QUILT 106 trial is assessing CD19-specific high-affinity natural killer (t-haNK) cells, first as a standalone therapy. Upon establishing safety, the treatment will then be combined with rituximab, a standard therapy for NHL, in patients with relapsed or refractory CD19+ and CD20+ B-cell NHL. This open-label study aims to enroll up to 10 participants and is taking place at clinical sites in Johannesburg, Pretoria, and Bloemfontein, South Africa.

*
In March 2024, Lantern Pharma initiated dosing for two participants in a Phase Ia/Ib clinical trial assessing its investigational compound LP-284 for individuals with relapsed or refractory non-Hodgkin's lymphoma (NHL). LP-284, a novel small molecule, operates through a synthetically lethal mechanism, targeting cancer cells with mutations in DNA damage repair pathways, ultimately leading to their eradication.

Non-Hodgkin Lymphoma Overview

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is a part of the body's immune system. Unlike Hodgkin lymphoma, another type of lymphoma, Non-Hodgkin lymphoma does not typically involve the presence of Reed-Sternberg cells.

Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight [https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:

*
AUTO4: Autolus

*
GB226: Genor Biopharma

*
Epcoritamab: AbbVie/ Genmab

*
Capivasertib: AstraZeneca

*
HRS-3738: Jiangsu Hengrui Medicine

*
PCLX-001: Pacylex Pharmaceuticals

*
ZN-d5: Zentera Therapeutics

*
TC-110: TCR2 Therapeutics

*
AB-101: Artiva Biotherapeutics

*
LOXO-305: Loxo Oncology

*
AB-205: Angiocrine Bioscience

*
Venetoclax: AbbVie

*
Tisagenlecleucel: Novartis

Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment

*
Non-Hodgkin Lymphoma Assessment by Product Type

*
Non-Hodgkin Lymphoma By Stage and Product Type

*
Non-Hodgkin Lymphoma Assessment by Route of Administration

*
Non-Hodgkin Lymphoma By Stage and Route of Administration

*
Non-Hodgkin Lymphoma Assessment by Molecule Type

*
Non-Hodgkin Lymphoma by Stage and Molecule Type

DelveInsight's Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:

Key companies developing therapies for Non-Hodgkin Lymphoma are - AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.

Non-Hodgkin Lymphoma Pipeline Analysis:

The Non-Hodgkin Lymphoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.

*
Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Non-Hodgkin Lymphoma Pipeline Market Drivers

*
Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.

Non-Hodgkin Lymphoma Pipeline Market Barriers

*
However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.

Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight

*
Coverage: Global

*
Key Non-Hodgkin Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others

*
Key Non-Hodgkin Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others

*
Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies

*
Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers

Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Non-Hodgkin Lymphoma Report Introduction

2. Non-Hodgkin Lymphoma Executive Summary

3. Non-Hodgkin Lymphoma Overview

4. Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Non-Hodgkin Lymphoma Pipeline Therapeutics

6. Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)

7. Non-Hodgkin Lymphoma Mid Stage Products (Phase II)

8. Non-Hodgkin Lymphoma Early Stage Products (Phase I)

9. Non-Hodgkin Lymphoma Preclinical Stage Products

10. Non-Hodgkin Lymphoma Therapeutics Assessment

11. Non-Hodgkin Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Hodgkin Lymphoma Key Companies

14. Non-Hodgkin Lymphoma Key Products

15. Non-Hodgkin Lymphoma Unmet Needs

16 . Non-Hodgkin Lymphoma Market Drivers and Barriers

17. Non-Hodgkin Lymphoma Future Perspectives and Conclusion

18. Non-Hodgkin Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonhodgkin-lymphoma-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-astrazeneca-baxter-bayer-bristol-myers-squibb-teva-pharma-eli-lilly]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Hodgkin Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma, Eli Lilly here

News-ID: 4124958 • Views:

More Releases from ABNewswire

Zenith Clipping Redefines Professional Photo Retouching with Unmatched Precision and Global Reach
Zenith Clipping Redefines Professional Photo Retouching with Unmatched Precision …
For over 15 years, Zenith Clipping has stood as a trusted global name in photo and video editing services, delivering flawless results to photographers, designers, agencies, and eCommerce businesses around the world. Based in Bangladesh, the company has built its reputation on speed, quality, and reliability, earning praise from clients across the United States, Canada, the United Kingdom, Australia, and beyond. Serving Clients Worldwide Zenith Clipping [https://zenithclipping.com/]collaborates with a wide range of
Qualipak Unveils Advanced Vial Filling Machine: Precision, Speed, and Reliability for Modern Production Lines
Qualipak Unveils Advanced Vial Filling Machine: Precision, Speed, and Reliabilit …
Image: https://www.abnewswire.com/upload/2025/10/bf9384cbc4022a0322d4242a58086d37.jpg Qualipak, a global leader in packaging machinery solutions, announces the launch of its high-performance Vial Filling Machine [https://qualipakmachines.com/vial-filling-machine/], engineered to deliver unmatched precision, hygiene, and operational efficiency for pharmaceutical, biotech, and cosmetic industries. Designed to fill small bottles or vials with liquid medicines, serums, and chemicals, the new system ensures every unit receives the exact dosage, eliminating waste while maintaining consistent quality. Fast, Accurate, and Efficient Vial Filling Performance The Vial
Fanatix Redefines Event Access: How Resale Marketplaces Are Changing the Game
Fanatix Redefines Event Access: How Resale Marketplaces Are Changing the Game
The way people buy and use tickets has changed a lot over the past few decades. From paper slips handed over at box offices to mobile barcodes scanned at the gate, ticketing has gone through a full transformation. Today, it's mostly digital and not just because it's convenient. It's safer, faster, and way more flexible than the systems we relied on in the past. But alongside that shift to digital
Illinois Divorce Lawyer Russell D. Knight Clarifies Intentional Infliction Of Emotional Distress In Illinois Divorce Cases
Illinois Divorce Lawyer Russell D. Knight Clarifies Intentional Infliction Of Em …
Chicago, Illinois - Illinois Divorce Lawyer Russell D. Knight of the Law Office of Russell D. Knight (https://rdklegal.com/intentional-infliction-of-emotional-distress-and-divorce-in-illinois) provides an in-depth explainer on how claims for intentional infliction of emotional distress intersect with divorce proceedings in Illinois. The guidance outlines when tort remedies apply outside the divorce docket, the standards Illinois courts use to evaluate such claims, and the timelines that govern potential actions, offering clarity to parties and professionals

All 5 Releases


More Releases for Hodgkin

Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%. Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/ Key Highlights Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025? The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The non hodgkin
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market. Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067 Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)